As biologics have come to supersede small molecules in the biopharma industry’s pipeline, the mounting complexity behind the ...

Despite a prolonged period of policy uncertainty in the U.S.—and the ripple effects across the global life sciences and ...

Bristol Myers Squibb and Hengrui Pharma signed a massive deal worth up to $15.2 billion. Takeda aims to cut 4,500 jobs in ...

When President Donald Trump rolled out his plan to levy a 100% tariff rate on patented pharmaceutical products and ...

With the FDA now rudderless following the revelation that commissioner Marty Makary, M.D., is stepping down, voices across biopharma have joined in support of the FDA’s former top drug regulator ...

AstraZeneca’s first foray with PD-L1 inhibitor Imfinzi as a treatment for bladder cancer was a flop. | Following an FDA ...

Eli Lilly has made a six-year, $50 million commitment to UNICEF USA to support efforts to improve the prevention, detection ...

With a new CEO prepared to take the reins next month and three key launches on deck for 2026 and 2027, Takeda is ready to ...

Generics juggernaut Sun Pharma is pulling one lot of a chemotherapy drug in the United States as the issue of particulate ...

BeOne Medicines has entered the BCL-2 arena, securing an FDA green light for Beqalzi that carves out a unique piece of territory ahead of a potential broader clash with market leader Venclexta. The ...

Merck KGaA made its largest acquisition in a decade in April 2025 when it snapped up Connecticut rare disease specialist ...

Taiwan’s Bora Group will shell out up to $127.5 million to acquire the CDMO business and manufacturing operations from ...